The safety of subcutaneously administered depot medroxyprogesterone acetate (104 mg/0.65 mL): A systematic review
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
CONTEXT: Depot medroxyprogesterone acetate (DMPA), a progestogen-only contraceptive injectable, has traditionally been formulated as a crystalline suspension delivered intramuscularly (IM) at a dose of 150mg/1.0mL. A new, lower dose formulation of DMPA (104mg/0.65mL) has been developed for subcutaneous administration (SC). Given its increasing global availability and public health relevance, DMPA-SC was prioritized for inclusion as a new method referenced in the World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use (MEC), 5th Edition. OBJECTIVE: This systematic review evaluated the published peer-reviewed literature regarding the safety of DMPA-SC among women with various characteristics or medical conditions. Results of this review informed the decision-making of a WHO Guideline Development Group in order to include recommendations on contraceptive eligibility within the revised MEC. METHODS: We searched PubMed and Cochrane Library databases to identify all relevant evidence published in peer-reviewed journals regarding the safety of DMPA-SC when used by women of reproductive age, particularly those with select characteristics or conditions specified in the MEC, from inception through June 2015. The quality of each individual study was assessed using the system for grading evidence developed by the United States Preventive Services Task Force. RESULTS: Fourteen studies met criteria for inclusion. Ten reported results relevant to DMPA users of varying age or with obesity, endometriosis or HIV; four compared the safety of DMPA-SC and DMPA-IM when used by general populations of healthy women. A randomized trial evaluating changes in bone mineral density among adult DMPA-SC and DMPA-IM users demonstrated no differences at 2years of follow-up. Limited evidence reported no consistent differences in weight change or bleeding patterns according to age; however, adolescents (<18years) were not included in any studies. Similar contraceptive efficacy, weight change, bleeding patterns and occurrence of other adverse effects among obese and nonobese DMPA-SC users were observed. Women with endometriosis using DMPA-SC over 6months had minimal decreases in bone mineral density, weight gain, few serious adverse events and experienced improved pain symptoms. Women living with HIV tolerated injection of DMPA-SC with rare complications. DMPA-SC and DMPA-IM also show therapeutic equivalence and similar effects on weight gain, changes in bleeding patterns and reports of other adverse effects when these different delivery systems were used by general populations of women. CONCLUSION: Evidence for use of DMPA-SC by women with select conditions and characteristics including age, obesity, endometriosis or HIV demonstrates that this method can generally be used safely in these contexts. Further, DMPA-SC and DMPA-IM appear to be therapeutically equivalent with similar safety profiles when used by healthy women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A. (2006) · Human Reproduction · doi:10.1093/humrep/dei290 · Cited by 179
Schlaff, W. D., Carson, S. A., Luciano, A., Ross, D., & Bergqvist, A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.1315 · Cited by 168
Kaunitz, A. M., Darney, P. D., Ross, D., Wolter, K. D., & Speroff, L. (2009) · Contraception · doi:10.1016/j.contraception.2009.02.005 · Cited by 123 · cited 9×
“Contraceptive efficacy Two fair quality reports presented results on three Phase 3 contraceptive trials and described contraceptive efficacy among obese women using DMPA-SC [5,9].”
BackgroundInfluentialCarr, B., Dmowski, W. P., O’Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014) · Reproductive Sciences · doi:10.1177/1933719114549848 · Cited by 114 · cited 4×
“Another Phase 2 randomized, controlled trial investigated use of a GnRH antagonist, elagolix, compared with DMPA-SC [18].”
BackgroundResultInfluential
Research works printed but not linked: 21
- Draper, 2006, Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception, Cochrane Database Syst Rev, 3, CD005214
- Westhoff, 2003, Depot-medroxyprogesterone acetate injection (Depo-Provera®): a highly effective contraceptive option with proven long-term safety, Contraception, 68, 75, 10.1016/S0010-7824(03)00136-7 · DOI
- Jain, 2004, Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera, Contraception, 70, 11, 10.1016/j.contraception.2004.01.011 · DOI
- Halpern, 2014, Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm, Contraception, 89, 31, 10.1016/j.contraception.2013.07.002 · DOI
- Jain, 2004, Contraceptive efficacy and safety of DMPA-SC, Contraception, 70, 269, 10.1016/j.contraception.2004.06.011 · DOI · Paper page
- Mohllajee, 2005, Keeping up with evidence a new system for WHO's evidence-based family planning guidance, Am J Prev Med, 28, 483, 10.1016/j.amepre.2005.02.008 · DOI
- Harris, 2001, Current methods of the US preventive services task force: a review of the process, Am J Prev Med, 20S, 21, 10.1016/S0749-3797(01)00261-6 · DOI · Paper page
- Arias, 2006, Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104mg, Contraception, 74, 234, 10.1016/j.contraception.2006.03.008 · DOI
- Westhoff, 2007, Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104mg/0.65mL, Contraception, 75, 261, 10.1016/j.contraception.2006.12.009 · DOI
- Segall-Gutierrez, 2010, Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously, Contraception, 81, 487, 10.1016/j.contraception.2010.01.021 · DOI
- Segall-Gutierrez, 2012, Effect of subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women, Contraception, 86, 739, 10.1016/j.contraception.2012.05.148 · DOI
- Segall-Gutierrez, 2012, Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use, Contraception, 85, 36, 10.1016/j.contraception.2011.04.016 · DOI
- Segall-Gutierrez, 2013, A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate, Eur J Contracept Reprod Health Care, 18, 199, 10.3109/13625187.2013.774358 · DOI
- Polis, 2014, Preference for Sayana(R) Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial, Contraception, 89, 385, 10.1016/j.contraception.2013.11.008 · DOI
- Goldstein, 2007, Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study, Fertil Steril, 87, 1267, 10.1016/j.fertnstert.2006.11.040 · DOI
- Burke, 2014, Observational study of the acceptability of sayana(R) press among intramuscular DMPA users in Uganda and Senegal, Contraception, 89, 361, 10.1016/j.contraception.2014.01.022 · DOI
- Lexchin, 2005, Implications of pharmaceutical industry funding on clinical research, Ann Pharmacother, 39, 194, 10.1345/aph.1E224 · DOI
- Grimes, 2005, Surrogate end points in clinical research: hazardous to your health, Obstet Gynecol, 105, 1114, 10.1097/01.AOG.0000157445.67309.19 · DOI · Paper page
- Williams, 2013, Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women, Contraception, 88, 401, 10.1016/j.contraception.2012.11.019 · doi:10.1016/j.contraception.2012.11.019
- Cameron, 2012, Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception, Contraception, 85, 458, 10.1016/j.contraception.2011.10.002 · DOI
- Prabhakaran, 2012, Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability, Contraception, 85, 453, 10.1016/j.contraception.2011.09.015 · doi:10.1016/j.contraception.2011.09.015
Cited by
ESHRE guideline: endometriosis
Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., et al. (2022) · Human Reproduction Open · doi:10.1093/hropen/hoac009 · Cited by 1,712
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies
Surrey, E., Taylor, H. S., Giudice, L., Lessey, B. A., Abrao, M. S., Archer, D. F., Diamond, M. P., Johnson, N. P., Watts, N. B., Gallagher, J. C., et al. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002675 · Cited by 139
Donnez, J., Taylor, H. S., Taylor, R. N., Akin, M. D., Tatarchuk, T. F., Wilk, K., Gotteland, J.-P., Lecomte, V., & Bestel, E. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.02.114 · Cited by 124
Metadata
- Authors
- Dragoman, M. V., & Gaffield, M. E.
- Venue
- Contraception
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 94
- Issue
- 3
- Pages
- 202-215
- ISSN
- 0010-7824 (ISSN-L)
- OpenAlex
- W2260878706
- Cited by
- 52
- References
- 4
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.